Second Genome competitors

Stephen R. Davis is a Chief Executive Officer & Board Member at ACADIA PHARMACEUTICALS INC.

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

John 'Chip' Scarlett is a Co-Founder at Covance and Board Member at CYTOMX THERAPEUTICS, INC. and is based in Menlo Park, California. He has worked as Board Member at GERON CORP, Board Member at Chiasma Inc, and Adjunct Assistant Professor of Medicine at Hospital of the University of Pennsylvania. John works or has worked as Various Positions at Mcneil Pharmaceuticals and Dir:Medical Research & Svcs at Mcneil Pharmaceuticals. He studied at University of Colorado Boulder between 1980 and 1982, University of Chicago - The Pritzker School of Medicine between 1973 and 1977, and Earlham College between 1969 and 1973.

John L. Higgins has over 14 years of corporate development, financing, strategic planning, commercialization, and investment banking experience in the biopharmaceutical industry. He is the chief executive officer of [Ligand Pharmaceuticals](https://www.crunchbase.com/organization/ligand-pharmaceuticals#/entity), a biotechnology company that focuses on the discovery and early-stage development of pharmaceuticals for medical needs in the United States. Prior to joining Ligand, Higgins was the chief financial officer; and executive vice president of finance, administration, and corporate development at Connetics Corporation, a public specialty pharmaceutical company, until its acquisition by Stiefel Laboratories, Inc. in 2006. During his service period of nearly 10 years at Connetics, he played a key leadership role in numerous strategic initiatives, including major acquisitions, divestitures, multiple product and technology licensing transactions, and financings. Prior to joining Connetics, Higgins was the executive vice president of corporate development at BioCryst Pharmaceuticals, Inc. and was a member of the health care investment banking team at Dillon, Read & Company, Inc. He has served numerous public and private corporate boards and currently is a director at BioCryst Pharmaceuticals, Inc. where he serves as chairman of the audit committee. Higgins earned a bachelor’s degree in Economics from Colgate University.

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Skip Wagner is a President and Chief Executive Officer at BioReliance and is based in College Station, Texas.